Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug - Hagens Berman
Novo Nordisk(NVO) Prnewswire·2025-02-28 14:30SAN FRANCISCO, Feb. 28, 2025 /PRNewswire/ -- Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obesity treatment, CagriSema. Hagens Berman urges investors who purchased Novo Nordisk shares and suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge of the trial and its design to contact the firm's attorneys.Class Period: Nov. 2, 2022 – Dec. 19, 2024Lead Plaintif ...